JonesResearch reiterates Buy rating on Trevi following positive CORAL update

JonesResearch notes Trevi Therapeutics (TRVI) shared positive update from the planned sample size re-estimation in ongoing Phase 2b CORAL trial in IPF-cough. In line with the firm’s bull case expectations, SSRE analysis suggested that CORAL trial should continue as planned, with no upsizing needed, keeping topline data on track for the first half of 2025. A favorable SSRE analysis, increases JonesResearch’s confidence that the statistical assumptions in CORAL are adequate. The drug is highly likely to show a clinically meaningful and statistically significant cough reduction in CORAL, the firm adds, reiterating a Buy rating on the shares.